Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer.
.png)
No hay comentarios:
Publicar un comentario